Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ejh.13502 http://scihub22266oqcxt.onion/10.1111/ejh.13502 32745304!7436812!32745304     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Haematol 2020 ; 105 (6): 751-754 Nephropedia Template TP {{tp|p=32745304|t=2020. Outcome of COVID-19 in multiple myeloma patients in relation to treatment |pdf=|usr=}}{{32745304}} gab.com Text Outcome of COVID-19 in multiple myeloma patients in relation to treatment JO: Eur J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=32745304 #FOAvip COVID-19 has emerged as a global pandemic. Cancer patients have been reported to be at higher risk for adverse outcome of COVID-19. Studies are ongoing to decipher the risk factors and risk groups among cancer patients as well as strategies to refine treatment approaches. Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19. We report that patients that succumbed to COVID-19 presented with either progressive tumor disease under daratumumab treatment or were in remission under lenalidomide-dexamethasone treatment. Twit Text FOAVip Outcome of COVID-19 in multiple myeloma patients in relation to treatment ????Eur J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=32745304 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32745304 #FOAvip English Wikipedia <ref>{{Cite pmid|32745304}}</ref> Outcome of COVID-19 in multiple myeloma patients in relation to treatment #MMPMID32745304 Susek KH; Gran C; Ljunggren HG; Alici E; Nahi H Eur J Haematol 2020[Dec]; 105 (6): 751-754 PMID32745304show ga COVID-19 has emerged as a global pandemic. Cancer patients have been reported to be at higher risk for adverse outcome of COVID-19. Studies are ongoing to decipher the risk factors and risk groups among cancer patients as well as strategies to refine treatment approaches. Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19. We report that patients that succumbed to COVID-19 presented with either progressive tumor disease under daratumumab treatment or were in remission under lenalidomide-dexamethasone treatment. |Antibodies, Monoclonal/administration & dosage/*adverse effects[MESH] |Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects[MESH] |Betacoronavirus/pathogenicity[MESH] |COVID-19[MESH] |Cohort Studies[MESH] |Coronavirus Infections/*diagnosis/drug therapy/immunology/mortality[MESH] |Dexamethasone/administration & dosage/*adverse effects[MESH] |Disease Progression[MESH] |Female[MESH] |Humans[MESH] |Immunomodulation[MESH] |Lenalidomide/administration & dosage/*adverse effects[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Myeloma/*diagnosis/drug therapy/immunology/mortality[MESH] |Pandemics[MESH] |Pneumonia, Viral/*diagnosis/drug therapy/immunology/mortality[MESH] |Prognosis[MESH] |Remission Induction[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Survival Analysis[MESH] |Thalidomide/administration & dosage/*adverse effects[MESH]Outcome of COVID-19 in multiple myeloma patients in relation to treatm(epmc).pdf DeepDyve Pubget Overpricing